Education
About Us
Working with TipRanks
Follow Us
Arcutis Biotherapeutics (ARQT)
NASDAQ:ARQT
ARQT Stock Chart & Stats
$26.88
-$0.25(-1.59%)
At close: 4:00 PM EST
$26.88
-$0.25(-1.59%)
Day’s Range― - ―
52-Week Range$11.13 - $31.77
Previous CloseN/A
Volume446.87K
Average Volume (3M)1.42M
Market Cap
$3.35B
Enterprise Value$3.35B
Total Cash (Recent Filing)$191.07M
Total Debt (Recent Filing)$113.77M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Feb 25, 2026EPS Estimate
0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding122,492,195
10 Day Avg. Volume1,242,249
30 Day Avg. Volume1,422,049
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)10.70
Price to Sales (P/S)8.57
P/FCF Ratio-15.00
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue10.54
Enterprise Value/Gross Profit11.71
Enterprise Value/Ebitda-139.89
Forecast
1Y Price Target
$32.00Price Target Upside19.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionAssuming responsibility for promotion to primary care physicians and pediatricians, combined with a planned sales force expansion and better tolerability versus an established topical competitor, should increase prescribing and market penetration.
Pipeline AdvancementPlans to initiate registrational trials for Zoryve and to begin a Phase 1 study of ARQ-324 create multiple clinical milestones that could materially affect the company’s future prospects if results are favorable.
Regulatory ApprovalPositive Phase 2 infant data demonstrating safety and meaningful efficacy for Zoryve cream strengthens the case for regulatory approval of a pediatric indication.
Bears Say
Competitive LandscapeA highly competitive dermatology market could limit Zoryve’s market share and constrain commercial uptake despite clinical advantages.
Expense And Profitability PressureHigher assumed research, development, and selling expenses increase the cost base and reduce near-term profitability in analyst models.
Product Concentration RiskDependence on a single commercial asset creates material concentration risk, leaving revenue exposed while other programs remain early-stage.
Arcutis Biotherapeutics News
ARQT FAQ
What was Arcutis Biotherapeutics’s price range in the past 12 months?
Arcutis Biotherapeutics lowest stock price was $11.13 and its highest was $31.77 in the past 12 months.
What is Arcutis Biotherapeutics’s market cap?
Arcutis Biotherapeutics’s market cap is $3.35B.
When is Arcutis Biotherapeutics’s upcoming earnings report date?
Arcutis Biotherapeutics’s upcoming earnings report date is Feb 25, 2026 which is in 15 days.
How were Arcutis Biotherapeutics’s earnings last quarter?
Arcutis Biotherapeutics released its earnings results on Oct 01, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.094 by $0.154.
Is Arcutis Biotherapeutics overvalued?
According to Wall Street analysts Arcutis Biotherapeutics’s price is currently Undervalued.
Does Arcutis Biotherapeutics pay dividends?
Arcutis Biotherapeutics does not currently pay dividends.
What is Arcutis Biotherapeutics’s EPS estimate?
Arcutis Biotherapeutics’s EPS estimate is 0.09.
How many shares outstanding does Arcutis Biotherapeutics have?
Arcutis Biotherapeutics has 122,492,195 shares outstanding.
What happened to Arcutis Biotherapeutics’s price movement after its last earnings report?
Arcutis Biotherapeutics reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.094. Following the earnings report the stock price went up 4.828%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics?
Currently, no hedge funds are holding shares in ARQT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcutis Biotherapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.00 (19.05% Upside)
$32.00 (19.05% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 90%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 23.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
119.96%
12-Months-Change
Fundamentals
Return on Equity
-28.17%
Trailing 12-Months
Asset Growth
-15.18%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
ARQT Stock 12 Month Forecast
Average Price Target
$32.00
▲(19.05% Upside)
Technical Analysis
Travere Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
9.46% Insiders
16.22% Mutual Funds
0.20% Other Institutional Investors
60.30% Public Companies and Individual Investors